New research suggests that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who stop conventional diet and exercise plans.
Research printed in a leading medical journal points out that while overweight people often shed about a fifth of their total mass while on the medication, the mass returns at an average rate of 0.8 kg per month once they quit.
"Users buying such drugs should be informed of the potential of quick weight regain when the medication ends," warns expert Dr. Susan Jebb.
That rate of regain suggests a reversion to starting weight in about a year and a half.
Weighing Approaches
The analysis, which reviewed dozens of trials involving over 9,000 of participants, contrasted the results of the injectable medications with conventional dieting.
Scientists note that individuals who lose weight through dieting generally see a slower creep back—approximately 100 grams monthly—post-intervention.
The Reason for the Rapid Rebound
Nutrition scientists suggest the way of the injections explains the heightened rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of the hormone levels far above than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement results in appetite is no longer kept in check, making excessive eating far more likely."
A Chronic Disease?
The NHS recommend the jabs for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts argue that, considering the high risk of weight regain, the treatment is often life-long.
This perspective is echoed by drug manufacturers, who say that the results "emphasize the long-term character of excess weight," comparing it to managing diseases like diabetes.
Patient Accounts
People who have come off the jabs describe a powerful return of cravings.
"I experienced something that goes on and you become starving," described an individual.
The struggle is compounded if individuals have not developed permanent dietary or behavioural changes during treatment.
Widespread Interest
Figures suggest that a significant number of people in the UK have tried these injections in the past year, with interest remaining high.
- Use is greater among females than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians caution that while these medications are effective agents for shedding pounds, they are not a standalone solution and long-term success relies on integrated lifestyle support.